SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will

-Phase 2b NASH trial as part of a potential Phase 2b/3 program expected to initiate in 1H21- -Topline data from recently initiated NASH paired-biopsy, open-label histology cohort expected by YE21- -Topline data from BIO89-100’s Phase 2 SHTG trial expected in 2H21- SAN FRANCISCO, Jan.

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc . (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing – – C onsistent results and baseline characteristics across biopsy confirmed and phenotypic NASH patients – – Positive, highly significant c orrelation between relative changes in liver

– Updated clinical data from BIO89-100 ’s Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting – – Planni ng to initiate the Phase 2b trial as part of the Phase 2b/3 program in NASH in 1H21 – – Topline results from BIO89-100’s Phase 2 SHTG trial expected

SAN FRANCISCO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that clinical data from its

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the

SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the pricing of an upsized

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that it has commenced an